Safety, Efficacy and Pharmacokinetics of C21 in Subjects With IPF

Phase 2 Completed 52 enrolled Vicore Pharma AB Orphan Reach Ltd. · collab

NaSingle-groupOpen-labelTreatment

Summary

This trial is a multi-centre, open-label, single-arm phase 2 trial investigating the safety, efficacy and pharmacokinetics of C21 in subjects with idiopathic pulmonary fibrosis.

Timeline

Start: 2020-11-13
Primary completion: 2024-03-30
Completion: 2024-03-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	C21	Unknown	100 mg	—

Safety, Efficacy and Pharmacokinetics of C21 in Subjects With IPF

Summary

Timeline

Drugs

Indications